Dermatologists' level of compliance with the prescription guidelines of isotretinoin for females of childbearing potential

International Journal of Dermatology

Volumn 50, Issue 9, 2011, Pages 1094-1098

  Alghamdi, Khalid M ^a   Khurram, Huma ^a   Asiri, Yousif A ^b   Mandil, Ahmed ^c  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

^b KING SAUD UNIVERSITY   (Saudi Arabia)

^c KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

ISOTRETINOIN;

ADULT; AGED; ARTICLE; CONTRACEPTION; CROSS-SECTIONAL STUDY; DERMATOLOGY; FEMALE; HEALTH EDUCATION; HUMAN; INAPPROPRIATE PRESCRIBING; INFORMED CONSENT; MAJOR CLINICAL STUDY; MALE; MEDICAL PRACTICE; PATIENT EDUCATION; PHYSICIAN; PRACTICE GUIDELINE; PREGNANCY; PREGNANCY RATE; PREGNANCY TERMINATION; PREGNANCY TEST; PRENATAL DRUG EXPOSURE; PRESCRIPTION; QUESTIONNAIRE; RISK ASSESSMENT; RISK REDUCTION; SAUDI ARABIA; SPONTANEOUS ABORTION; TERATOGENICITY;

ABORTION, INDUCED; ACNE VULGARIS; ADULT; CONTRACEPTION; DERMATOLOGIC AGENTS; DERMATOLOGY; FEMALE; GUIDELINE ADHERENCE; HUMANS; ISOTRETINOIN; MALE; PREGNANCY; QUESTIONNAIRES; SAUDI ARABIA; TERATOGENS;

EID: 80051915405     PISSN: 00119059     EISSN: 13654632     Source Type: Journal    
DOI: 10.1111/j.1365-4632.2011.04875.x     Document Type: Article

References (28)

1. Medical Economics Company. Physicians' Desk Reference, 53rd edn. Montvale, New Jersey: Medical Economics Company, 1999.
2. Purdy S, Berker D. Acne. BMJ 2006; 333: 949-953.
3. ®-exposed pregnancies-California, 1999. Arch Dermatol 2000; 136: 686-687.
4. Lammer EJ, Chen DT, Hoar RM, et al. Retinoic acid embryopathy. N Engl J Med 1985; 313: 837-841.
5. Adams J, Lammer EJ. Neurobehavioral teratology of isotretinoin. Reprod Toxicol 1993; 7: 175-177.
6. Zarowny DP. Accutane Roche: risk of teratogenic effects. Can Med Assoc J 1984; 131: 273.
7. Mitchell AA, Van Bennekom CM, Louik C. A pregnancy prevention program in women of childbearing age receiving isotretinoin. N Engl J Med 1995; 333: 101-106.
8. Brinker A, Kornegay C, Nourjah P. Trends in adherence to a revised risk management program designed to decrease or eliminate isotretinoin-exposed pregnancies: evaluation of the Accutane SMART program. Arch Dermatol 2005; 141: 563-569.
9. US Food and Drug Administration. FDA and manufacturers of Accutane and its generics to implement iPLEDGE Program on March 1, 2006. Web site available at: [Accessed 20 Dec 2009].
10. Department of Health and Human Services. Update on birth defects with isotretinoin. FDA Drug Bull 1984; 14: 15-16.
11. Centre for Disease Control and Prevention (CDC). Birth defects caused by isotretinoin - New Jersey. Morb Mortal Wkly Rep 1988; 37: 171-172.
12. Schonfeld TL, Amoura NJ, Kratochvil CJ. iPLEDGE allegiance to the pill: evaluation of year 1 of a birth defect prevention and monitoring system. J Law Med Ethics 2009; 37: 104-117.
13. Honein MA, Paulozzi LJ, Erickson JD. Continued occurrence of Accutane-exposed pregnancies. Teratology 2001; 64: 142-147.
14. Food and Drug Administration. Briefing document for iPLEDGE year one update, United States Department of Health and Human Services, available at [Accessed 20 Dec 2009].
15. Darves B. Dermatologists frustrated with problematic iPledge program. Medscape Med News 9 March 2006 [Accessed 20 Dec 2009].
16. Koren G, Avner M, Shear N. Generic isotretinoin: a new risk for unborn children. Can Med Assoc J 2004; 170: 1567-1568.
17. Abroms L, Maibach E, Lyon-Daniel K, et al. What is the best approach to reducing birth defects associated with isotretinoin? PLoS Med 2006; 3: e483.
18. Boucher N, Beaulac-Baillargeon L. Pregnancy prevention among women taking isotretinoin, failure to comply with the recommendations. Can Fam Physician 2006; 52: 339.
19. Tang MB, Tan ES, Tian EA, et al. Electronic e-isotretinoin prescription chart: improving physicians' adherence to isotretinoin prescription guidelines. Aus J Dermatol 2009; 50: 107-112.
20. El Hamri N. Approaches to family planning in Muslim communities. J Fam Plann Reprod Health Care 2010; 36: 27-31.
21. Islamic Research Foundation International. Abortion [cited 20 Dec 2009].
22. Aramesh K. Abortion: an Islamic ethical view. Iran J Allergy Asthma Immunol 2007; 6: 29-33.
23. Steinberg A. Abortion for fetal CNS malformations: religious aspects. Childs Nerv Syst 2003; 19: 592-595.
24. Ethics of abortion. Available at; [Accessed 20 Dec 2009].
25. Asman O. Abortion in Islamic countries - legal and religious aspects. Med Law 2004; 23: 73-89.
26. ® Use in Women. Brookline, Mass: US Food and Drug Administration, 2000. Available from: [Accessed 20 Dec 2009].
27. Atanackovic G, Koren G. Fetal exposure to oral isotretinoin: failure to comply with the Pregnancy Prevention Program. Can Med Assoc J 1999; 160: 1719-1720.
28. Bérard A, Azoulay L, Koren G, et al. Isotretinoin, pregnancies, abortions and birth defects: a population-based perspective. Br J Clin Pharmacol 2007; 63: 196-205.